Inhibition of rat liver fibrogenesis through noradrenergic antagonism

Liliane Dubuisson, Alexis Desmoulière, Boris Decourt, Laetitia Evadé, Christiane Bedin, Liliane Boussarie, Laurence Barrier, Michel Vidaud, Jean Rosenbaum

Research output: Contribution to journalArticlepeer-review

68 Scopus citations

Abstract

The effect of adrenergic innervation and/or circulating catecholamines on the function of liver fibrogenic cells is poorly understood. Our aim was to investigate the effects of noradrenergic antagonism on carbon tetrachloride (CCl4)-induced liver fibrosis in rats. Two weeks of CCl4 induced a ∼5-fold increase in the area of fibrosis as compared with controls. The addition of 6-hydroxydopamine (OHDA), a toxin that destroys noradrenergic fibers, decreased fibrosis by 60%. After 6 weeks of CCl4, the area of fibrosis increased about 30-fold in CCl4-treated animals and was decreased by 36% with OHDA. At 2 weeks, OHDA abrogated the CCl4-induced increase in mRNA level of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), an inhibitor of extracellular matrix degradation, and it greatly reduced it at 6 weeks. Finally, when rats treated with CCl4 for 2 weeks also received prazosin, an antagonist of α1-adrenergic receptors, fibrosis was decreased by 83%. In conclusion, destruction of noradrenergic fibers or antagonism of noradrenergic signaling through α1 receptors inhibited the development of liver fibrosis. Because adrenoreceptor antagonists have a very sound safety profile, they appear as attractive drugs to reduce liver fibrogenesis.

Original languageEnglish (US)
Pages (from-to)325-331
Number of pages7
JournalHepatology
Volume35
Issue number2
DOIs
StatePublished - 2002

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Inhibition of rat liver fibrogenesis through noradrenergic antagonism'. Together they form a unique fingerprint.

Cite this